Saurabh Kapoor, MD
Advanced Heart Failure and Transplant Cardiology · Englewood, NJNPI 1235376864
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Pfizer accounts for 75.3% of it on its own, with 35 other manufacturers making up the rest. 2025 is the largest year on record at $9,806, more than ten times the $890 reported in 2019.
Across 242 payments — averaging $112.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$21K
- Abbott$2K
- Abiomed$1K
- Novartis$822
- Actelion Pharmaceuticals US, Inc.$517
- AstraZeneca$211
- plus $2K from 30 others
Across 14 payments — averaging $4124.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Array Biopharma Inc$23K
- Pfizer$19K
- Amgen$16K
What the payments were for
- Consulting fees$4,55017%
- Speaking & faculty fees$14,70054%
- Travel & lodging$1,1954%
- Food & beverage$6,69425%
- Education$1761%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 37 | $20,575 |
| Abbott | 44 | $2,371 |
| Abiomed | 12 | $1,200 |
| Novartis | 55 | $822 |
| Actelion Pharmaceuticals US, Inc. | 24 | $517 |
| AstraZeneca | 13 | $211 |
| Cvrx, Inc. | 2 | $198 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $194 |
| Paragonix Technologies, Inc. | 3 | $160 |
| Impulse Dynamics (USA) Inc. | 2 | $137 |
| Eurofins Viracor, LLC | 1 | $128 |
| Merck | 7 | $115 |
| Maquet Cardiovascular L.L.C. | 3 | $95 |
| Boehringer Ingelheim | 4 | $58 |
| Akcea Therapeutics, Inc. | 4 | $57 |
| Bridgebio Pharma, Inc. | 2 | $38 |
| Bayer | 2 | $35 |
| Edwards Lifesciences | 1 | $34 |
| Alnylam Pharmaceuticals Inc. | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Daxor Corporation | 1 | $29 |
| One Lambda, Inc. | 1 | $28 |
| Johnson & Johnson | 1 | $27 |
| Medtronic | 1 | $25 |
| Astellas Pharma US Inc | 1 | $21 |
| La Jolla Pharmaceutical Company | 1 | $21 |
| Endotronix, Inc. | 1 | $21 |
| Atricure, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
| Invivyd Inc | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Angiodynamics, Inc. | 1 | $13 |
| Boston Scientific | 1 | $13 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$16,978
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,050
- Impella$946
- OPTIMIZER$228
- HeartMate Touch$176
- THORATEC HEARTMATE 3$151
- Barostim Neo System$150
- CARDIOMEMS$146
- VYNDAMAX$107
How this compares
$27,314 in reported general payments places this provider in the 70th percentile of 21 advanced heart failure and transplant cardiology providers in New Jersey.
See all advanced heart failure and transplant cardiology providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 13 | $421,876 |
| Amphotericin B Liposome | 15 | $106,061 |
| EntrestoSacubitril/Valsartan | 62 | $78,493 |
| FarxigaDapagliflozin Propanediol | 28 | $35,025 |
| JardianceEmpagliflozin | 26 | $25,475 |
| VerquvoVericiguat | 14 | $14,606 |
| MicafunginMicafungin Sodium | 20 | $7,604 |
| Hydralazine Hcl | 21 | $421 |
| Torsemide | 17 | $256 |
| Potassium Chloride | 12 | $221 |
| Spironolactone | 38 | $220 |
| Carvedilol | 22 | $188 |
| Pantoprazole Sodium | 12 | $117 |
| Atorvastatin Calcium | 25 | $82 |
| Furosemide | 14 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax | $20,575 | $421,87613 claims |
| NovartisEntresto | $822 | $78,49362 claims |
| AstraZenecaFarxiga | $211 | $35,02528 claims |
| Boehringer IngelheimJardiance | $58 | $25,47526 claims |
| MerckVerquvo | $115 | $14,60614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 21 advanced heart failure and transplant cardiology providers in New Jersey.
Other advanced heart failure and transplant cardiology in Englewood
- Abhishek SinghMorristown$283K
- Kanika ModyHackensack$107K
- Kulpreet BarnBarnegat$92K
- Robert MohapatraSewell$84K
- Saad AhmadMorristown$74K
- Mark ZuckerMorristown$44K
- Ketan GalaCherry Hill$18K
- Raul FloresMorristown$11K
- Ahmed SeliemCamden$8K
- Eman RashedNewark$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.